OncoMed Pharmaceuticals Inc., of Mountain View, has raised $33.12 million in Series B funding, according to a regulatory filing. Adams Street Partners was joined by return backers like Latterell Venture Partners, Morgenthaler Ventures, U.S. Venture Partners and The Vertical Group. OncoMed focuses on something called “cancer stem cells,” which aren’t really stem cells, but are called that because of their ability to replicate within solid tumors. The company isn’t talking about this deal yet, but here’s a piece I wrote on OncoMed last year. Still one of the most exciting companies I’ve ever covered. (Source: PE Wire.)